Active Ingredient: Eptinezumab
Eptinezumab is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
100 - 300 mg
From 100 To 300 mg once every 84 day(s)
The recommended dose is 100 mg administered by intravenous infusion every 12 weeks. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 12 weeks.
The need for dose escalation should be assessed within 12 weeks after initiation of the treatment. When switching dosage, the first dose of the new regimen should be given on the next scheduled dosing date.
Overall benefit and continuation of treatment should be assessed 6 months after initiation of the treatment. Any further decision to continue the treatment should be made on an individual patient basis.
Do not administer eptinezumab as a bolus injection.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
